ReShape Lifesciences Inc.
RSLS
$0.6355
$0.00050.08%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.36% | -12.82% | -15.00% | -36.27% | -22.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.36% | -12.82% | -15.00% | -36.27% | -22.98% |
| Cost of Revenue | -1.61% | -21.60% | -26.72% | -90.73% | 24.39% |
| Gross Profit | 11.72% | -5.03% | -4.82% | 15.13% | -38.70% |
| SG&A Expenses | -27.23% | -39.66% | -54.84% | -52.94% | -39.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.92% | -35.83% | -47.54% | -53.52% | -31.44% |
| Operating Income | 43.25% | 48.77% | 60.75% | 63.78% | 36.30% |
| Income Before Tax | 55.40% | 54.71% | 17.71% | 89.91% | 71.86% |
| Income Tax Expenses | 100.00% | 275.00% | 0.00% | 155.36% | 100.83% |
| Earnings from Continuing Operations | 55.26% | 54.34% | 17.62% | 89.69% | 71.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.26% | 54.34% | 17.62% | 89.69% | 71.00% |
| EBIT | 43.25% | 48.77% | 60.75% | 63.78% | 36.30% |
| EBITDA | 42.48% | 48.28% | 60.52% | 59.97% | 29.46% |
| EPS Basic | 94.77% | 94.12% | 94.00% | -- | -- |
| Normalized Basic EPS | 93.31% | 92.65% | 94.01% | -- | -- |
| EPS Diluted | 94.77% | 94.12% | 94.00% | -- | -- |
| Normalized Diluted EPS | 93.31% | 92.65% | 94.01% | -- | -- |
| Average Basic Shares Outstanding | 755.29% | 676.61% | 1,270.85% | -- | -- |
| Average Diluted Shares Outstanding | 755.29% | 676.61% | 1,270.85% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
